Novartis AG Keeps CEO Pay Steady, But Incoming Chairman Pay Drops

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Novartis kept pay for its Chief Executive Joe Jimenez steady, after cutting it last year before a Swiss vote to force companies to accept shareholder limits on executive rewards. The Basel-based drugmaker, typically the first Swiss blue-chip company pay to disclose pay, said on Wednesday Jimenez was paid 13.2 million Swiss francs ($14.69 million) in total for 2013, more than 3 million francs of it in cash. It earlier posted lower-than-expected fourth-quarter profit and said it was looking at options, such as joint ventures, for its three smaller businesses.

Help employers find you! Check out all the jobs and post your resume.

Back to news